Professor Tom Foltynie The Bydureon Exenatide Phase Lll Trial 2019

Professor Tom Foltynie The Bydureon Exenatide Phase Lll Trial 2019 Professor tom foltynie, university college london presents the bydureon phase 3 trial at cure parkinson's 2019 autumn research update meeting. Promising breakthrough: bydureon's impact on parkinson's research • bydureon's impact on parkinson's • discover how the groundbreaking bydureon (exenatide) p.

Professor Tom Foltynie The Bydureon Phase 3 Trial Youtube About press copyright contact us creators advertise developers terms privacy policy & safety how works test new features nfl sunday ticket press copyright. One of the sub studies is a proof of concept imaging study* led by professor tom foltynie at university college london (ucl) – professor foltynie is the lead investigator of the entire programme. this sub study will provide imaging data to the phase 3 trial and supplementary evidence for bydureon as a potentially disease modifying treatment. This phase 3 clinical trial is testing the efficacy of exenatide in a large cohort of people with parkinson’s and is the next stage in a programme of trials and research studies to determine whether this glp 1 diabetes drug is a beneficial treatment. this two year study involves 200 people with parkinson’s taking place in six sites around. Following encouraging results recently published in the journal of clinical investigation describing the progress of a cohort of patients treated with exenatide for their parkinson’s disease (pd), nihr eme has awarded a grant of £2.3 million to professor tom foltynie to pursue this avenue of research.

The Bydureon Exenatide Phase 3 Trial Cure Parkinson S This phase 3 clinical trial is testing the efficacy of exenatide in a large cohort of people with parkinson’s and is the next stage in a programme of trials and research studies to determine whether this glp 1 diabetes drug is a beneficial treatment. this two year study involves 200 people with parkinson’s taking place in six sites around. Following encouraging results recently published in the journal of clinical investigation describing the progress of a cohort of patients treated with exenatide for their parkinson’s disease (pd), nihr eme has awarded a grant of £2.3 million to professor tom foltynie to pursue this avenue of research. Exenatide and parkinson’s. the results of a large phase 2 clinical trial in 2017 showed that exenatide, a drug used to treat diabetes, may slow the progression of parkinson’s. these results added further evidence to exenatide’s potential as a drug that might slow the progression of parkinson’s and paved the way for the larger phase 3. Methods and analysis this is a phase 3, multicentre, double blind, randomised, placebo controlled trial of exenatide at a dose of 2 mg weekly in 200 participants with mild to moderate pd.